Since 1968, hydroxyurea has been used as a radiosensitizer in combination modality treatments for carcinoma of the cervix. The drug has shown an advantage over placebo in several randomized trials. Although hydroxyurea is given orally on an outpatient basis, it has not gained widespread acceptance. Previous reports are reviewed and possible future uses are discussed.
|Original language||English (US)|
|Number of pages||5|
|Journal||Seminars in oncology|
|Issue number||3 SUPPL. 9|
|State||Published - Jun 1992|
ASJC Scopus subject areas